SafeSEQ Ultra-sensitive NGS liquid biopsy
Our new SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with sensitivity equivalent to our OncoBEAM digital PCR liquid biopsy from across a broader range of genomic regions.
OncoBEAM set the gold standard for ctDNA analysis being the most sensitive digital PCR approach available. It has been used to detect subclonal resistance mutations, such as those in ESR1 for breast cancer patients on adjuvant aromatase inhibitor therapy who demonstrate endocrine resistance.
With robust detection as low as 0.02% mutant allele frequency (MAF), SafeSEQ ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response.
Our cost-effective and industry-leading ultra-sensitive NGS liquid biopsy solutions identify tumor mutations across cancer types for a range of intended uses:
Inform therapy selection
Dynamically monitor tumor response
Identify molecular mediators of resistance
Detect minimal residual disease (MRD) at a variant level...
More Info Less Info